Campus alert status is orange: For the latest campus alert status, news and resources, visit umassmed.edu/coronavirus.

Search Close Search
Search Close Search

Print

Terence Flotte elected to American Society of Gene & Cell Therapy leadership team

UMass Medical School Communications

April 09, 2019
  flotte-2018.png
 

Terence R. Flotte, MD

Terence R. Flotte, MD, the Celia and Isaac Haidak Professor of Medical Education, executive deputy chancellor, provost and dean of the School of Medicine, has been elected to the American Society of Gene & Cell Therapy (ASGCT) leadership team. Dr. Flotte will serve as secretary of the board.

The ASGCT is welcoming five incoming members of its leadership team at the organization’s 22nd annual meeting, April 29-May 2, in Washington, D.C. The newly elected leaders will serve a three-year term.

Flotte has been an ASGCT member since the society’s founding and committee participant on the Respiratory Disease Committee and as chair of previous iterations of both the Clinical and Regulatory Affairs Committee, and the Advisory Council. He will assume the role of secretary with ASGCT, and will be instrumental in developing the program for upcoming ASGCT annual meetings.

Flotte’s research investigates delivery of therapeutic genes and miRNA with recombinant AAV vectors for monogenic diseases such as alpha-1 antitrypsin deficiency and cystic fibrosis. In 1995, his lab was the first to use recombinant adeno-associated virus (rAAV) in humans when they conducted cystic fibrosis clinical trials.